Screener Summaries Updates Institutions Sign In More Updates › Leadership & Pay › CLYM Leadership & Pay · Jul 1, 2026
On June 29, 2026, Andrew Levin resigned from the Board of Directors and Breanna O'Reilly, Ph.D., was elected as a new… CLYM Climb Bio, Inc.
On June 29, 2026, Andrew Levin resigned from the Board of Directors and Breanna O'Reilly, Ph.D., was elected as a new director. Dr. O'Reilly's term expires in 2027 and she will receive an annual cash retainer of $40,000 and a stock option grant of 70,284 shares at an exercise price of $13.36 per share. Climb Bio, Inc. is a biotechnology company focused on developing therapeutic solutions.
More from Climb Bio, Inc. Climb Bio reports Q3 net loss of $14.6 million; holds $227.6 million in cash Nov 5, 2026 Climb Bio reports initial Phase 2 PrisMN data for budoprutug in pMN showing 70% PLA2R reduction Oct 26, 2026 Climb Bio reports CLYM116 Phase 1 data showing ~70% Gd-IgA1 reduction at 12 weeks Oct 23, 2026 On September 3, 2026, Climb Bio announced positive initial data from its Phase 1 trial of CLYM116, an anti-APRIL… Sep 3, 2026 Climb Bio reported second quarter 2026 financial results on August 6, 2026, showing a net loss of $13.5 million… Aug 6, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
